Categories: News

GIGABYTE Redefines Human-AI Interaction at CES 2026 with a Fully Immersive, Participatory Experience

TAIPEI, Jan. 13, 2026 /PRNewswire/ — GIGABYTE unveils a new vision for how people engage with artificial intelligence at CES 2026, taking place from January 6 to January 9. Under the theme “The World as Prompt,” the company presents an immersive, AI-driven experience that brings together advanced laptop technologies, intelligent software, and human-centered interaction to explore new models of human-AI collaboration.

- Advertisement -

Upon entering the experience, visitors generate a personalized AI digital twin that serves as a digital passport throughout the journey. This avatar connects participants to a series of interactive AI product experiences and ultimately generates a short mission highlight video as a personalized takeaway from their visit. 

- Advertisement -

Human-AI interaction comes to life through GIGABYTE RTX 50 series laptops and GiMATE, GIGABYTE’s smart AI Mate. Through natural voice-based interaction, GiMATE adapts to different usage scenarios, from creative work and coding to productivity and entertainment, demonstrating how AI can respond intuitively to individual needs and lifestyles. Real-time AI processing and on-device AI workloads enable responsive interaction without relying on cloud-based systems. 

- Advertisement -

The experience also offers a closer look at how hardware design supports next-generation AI performance. GIGABYTE’s WINDFORCE INFINITY EX thermal architecture allows visitors to visually explore the internal structure beneath the keyboard, illustrating how advanced cooling design helps sustain high-performance AI and GPU workloads. Newly introduced laptops, including the AERO X16 Copilot+ PC powered by AMD Ryzen™ AI 9 400 Series processors and NVIDIA® RTX™ graphics, highlight GIGABYTE’s vision of portable AI computing designed to move seamlessly between work, play, and creativity. 

- Advertisement -

The journey culminates with the AORUS MASTER 16 (2026), showcasing refined lightweight design, premium materials, and the return of an OLED display with a high refresh rate for immersive gaming and creation. AI-enhanced workflows, including AI-assisted coding powered by GiMATE, demonstrate how performance and intelligence converge on a single platform. 

- Advertisement -

Through its CES 2026 experience, GIGABYTE illustrates a future where AI moves beyond automation to become a creative collaborator, responding not only to commands, but to human expression. Visitors can experience GIGABYTE’s Product Showcase at CES 2026, located at Venetian Expo, Level 3, Lido 3005.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2859235/CES_2026_GIGABYTE_SUITE_KV.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/gigabyte-redefines-human-ai-interaction-at-ces-2026-with-a-fully-immersive-participatory-experience-302659226.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

3 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

3 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

3 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

3 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

3 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

3 hours ago